好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

GAD 65 Antibody Encephalitis Presenting as New Onset Refractory Status Epilepticus (NORSE)
Autoimmune Neurology
P2 - Poster Session 2 (5:30 PM-6:30 PM)
15-023
N/A

NORSE is defined as a new onset of refractory status epilepticus without a clear active structural, metabolic or toxic cause in a patient without active epilepsy. In up to half the cases a possible or probable cause is found- most commonly autoimmune or paraneoplastic encephalitis while infectious causes are less common.

 

A 64-year-old female was presented with sudden onset altered behavior consisting of reduced word output and unresponsiveness. She had intermittent jerky movements of the head and eyelid fluttering. EEG monitoring demonstrated non-convulsive status epilepticus originating from the right frontotemporal region. Antiepileptic drugs (AEDs) given included Ativan, Keppra, and Vimpat. She was later started on Midazolam infusion and Depakote, Clobazam and Topamax were added. The seizures persisted and she was placed in pentobarbital coma. Brain CT, CT angiogram and MRI were within normal. CSF revealed positive oligoclonal bands. Workup for infectious, inflammatory and autoimmune/paraneoplastic disease was negative except for markedly elevated serum GAD 65 Antibody at >250 units/ml (normal <5) and the levels have remained elevated throughout her hospitalization. The patient received multiple immunosuppressive medications including high-dose daily prednisone, intravenous immunoglobulin, rituximab, and plasma exchange without significant improvement in status epilepticus. Attempts to wean pentobarbital have been followed by recurrence of seizures and this medication has been continued.

N/A
N/A
Autoimmunity is a frequent cause of intractable epilepsy accounting for 20% of the cases. It is prudent to test all patients with new-onset drug-refractory epilepsy for antibodies in the serum and spinal fluid as patients require immunotherapy in addition to AEDs. Literature indicates that autoimmune epilepsy varies in its response to immunotherapy with patients having VGKC antibodies being more responsive to treatment and those with GAD 65 antibodies least responsive as demonstrated by our patient.
Authors/Disclosures
Amin Sanei Moghaddam, MD (ProMedica)
PRESENTER
Dr. Sanei Moghaddam has nothing to disclose.
Ajaz Sheikh, MD (ProMedica Neurosciences Center) Dr. Sheikh has nothing to disclose.
Noor A. Pirzada, MD, FAAN Dr. Pirzada has nothing to disclose.